Homburger advised Santhera in connection with its up to CHF 69 m Royalty and Debt Financing

On June 18, 2024, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had entered into a royalty monetization financing totaling up to USD 38 m with R-Bridge, an affiliate of CBC Group,

Homburger advised ZKB as Sole Lead Manager of SGKB’s CHF 200 m Tier 2 issuance

On May 30, 2024, St.Galler Kantonalbank AG (SGKB) successfully issued CHF 200 m 2.4% Tier 2 bonds due 2034.

Homburger advised Lotus Bakeries on its strategic partnership with Mondelēz International to expand and grow the Lotus Biscoff® cookie brand

On June 13, 2024, Lotus Bakeries and Mondelēz International announced a strategic partnership to expand and grow the Lotus Biscoff® cookie brand in India and to create co-branded chocolate innovations in key markets.

Homburger advised Apellis Pharmaceuticals, Inc. on its senior secured USD 475 m financing

On May 13, 2024, Apellis Pharmaceuticals completed Apellis group’s USD 475 m senior secured credit facilities financing.

Homburger advised NZZ on the acquisition of a strategic 25%-stake in APG|SGA, a leading Out-of-Home Media company in Switzerland

On May 30, 2024, Aktiengesellschaft für die Neue Zürcher Zeitung (NZZ) announced the acquisition of a 25%-stake in APG SGA SA (APG|SGA) from the two anchor shareholders JCDecaux SE and Pargesa Asset Management S.A. for a total consideration of CHF 165 m.

Homburger advised UBS Group AG on its issuance of USD 1.75 bn Fixed Rate/Fixed Rate Callable Senior Notes under its Senior Debt Programme

On May 13, 2024, UBS Group AG successfully completed its issuance of USD 1.75 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due September 2030 under its Senior Debt Programme.

Homburger advised on the sale of Biopas to Swixx Biopharma

On May 22, 2024, Swixx Biopharma, a Swiss-based global commercial platform dedicated to unlocking access to innovative medicines worldwide, announced its strategic expansion into Latin America by acquiring Laboratorios Biopas.

Homburger advised Sonova AG on CHF 400 m credit facility

Homburger acted as counsel to Sonova AG in its capacity as borrower in connection with a Swiss law-governed CHF 400 m term and revolving credit facility agreement with UBS Switzerland AG as mandated lead arranger and agent for an international bank syndicate.

Homburger advised UBS Switzerland AG in connection with BKW AG’s new CHF 1 bn credit facility

 Homburger acted as counsel to UBS Switzerland AG in its capacity as mandated lead arranger, bookrunner and agent in connection with BKW AG’s new CHF 1 bn Swiss law governed revolving credit facility.

Homburger advised ADC Therapeutics SA on its USD 105 m Underwritten Offering of Common Shares and Pre-Funded Warrants

On May 8, 2024, ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company headquartered in Switzerland,